Y-Intercept (HK)
NAMS icon

Y-Intercept (HK)’s NewAmsterdam Pharma NAMS Stock Holding History

Y-Intercept (HK)’s Portfolio NAMS Stock Details NAMS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q3 		– Sell
-78,136
Closed -$2.65M – 1917
2026
Q2 		$2.65M Buy
+78,136
New +$2.57M 0.05% 543
2024
Q3 		– Sell
-14,607
Closed -$281K – 1626
2024
Q2 		$281K Sell
14,607
-11,601
-44% -$233K 0.02% 1049
2024
Q1 		$620K Buy
+26,208
New +$532K 0.05% 603

Other funds holding NAMS

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.32T AUM 44.66% 1-Year Est. Return
Medicxi Ventures Management
Medicxi Ventures Management St. Helier, Jersey $127M AUM 21.77% 1-Year Est. Return
Aberdeen Group
Aberdeen Group Edinburgh, United Kingdom $72.4B AUM 31.32% 1-Year Est. Return
TimesSquare Capital Management
TimesSquare Capital Management New York $6.12B AUM 30.01% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $608B AUM 32.77% 1-Year Est. Return
Mizuho Markets Cayman
Mizuho Markets Cayman Grand Cayman, Cayman Islands $2.12B AUM 114.77% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $179B AUM 29.92% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $500B AUM 36.84% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $362B AUM 34.89% 1-Year Est. Return
Peregrine Capital Management
Peregrine Capital Management Minneapolis, Minnesota $2.95B AUM 28.43% 1-Year Est. Return

Y-Intercept (HK)'s NAMS Position: Q3 2026 in Review

Y-Intercept (HK) sold out of NewAmsterdam Pharma (NAMS) in Q3 2026, closing a stake of 78,136 shares — an estimated $2.65M sold.

Y-Intercept (HK) first reported a position in NAMS in Q1 2024 and held it in 3 quarters. The position peaked at $2.65M in Q2 2026. 70 funds tracked by Wall St. Rank hold NAMS as of Q3 2026.

  • Y-Intercept (HK) reported no remaining NewAmsterdam Pharma position as of Q3 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 78,136 NewAmsterdam Pharma shares in Q3 2026, an estimated $2.65M.
  • Y-Intercept (HK) first reported a position in NewAmsterdam Pharma in Q1 2024 and held it in 3 quarters.
  • Y-Intercept (HK)'s NewAmsterdam Pharma position peaked at $2.65M in Q2 2026.
  • 70 funds tracked by Wall St. Rank held NewAmsterdam Pharma as of Q3 2026.

Based on Y-Intercept (HK)'s 13F filing for Q3 2026, filed 16 Oct 2026.